The association between phosphodiesterase type 5 (PDE5) inhibitors and melanoma risk is controversial.
have prompted several observational studies assessing the association between PDE5 inhibitors and risk for development of melanoma. [5] [6] [7] [8] [9] In 2014, the first cohort study on this subject (Li et al) among a United Statesebased cohort of male health professionals indicated that self-reported use of PDE5 inhibitors was significantly associated with higher risk for development of melanoma compared with nonuse. 5 However, their results were based on only 142 patients with melanoma, of whom 14 used sildenafil. Since the article by Li et al, 4 additional studies have been published. A nested casecontrol study (Loeb et al [2015] ) suggested a modest association between PDE5 inhibitors and risk for development of melanoma but did not meet several of Hill's causality criteria. 6 However, 2 epidemiologic studies indicated no association. 7, 9 Given these inconsistencies among individual studies, it is not possible to determine whether there is a link between PDE5 inhibitors and risk for development of melanoma.
PDE5 inhibitors are an effective intervention and are recommended as first-line treatment for erectile dysfunction, which affects more than 18 million men in the United States, or up to 20% of men age 20 years or older. 10 With the expiration of the patents on sildenafil and other PDE5-inhibiting drugs, lower costs and more direct-to-consumer advertising will certainly increase the number of users. Understanding the possible connections between PDE5 inhibitors and the incidence of melanoma is an important public health issue.
We therefore conducted a study-level metaanalysis of available evidence from observational studies to quantify the possible association between use of PDE5 inhibitors and risk for development of skin cancers. No randomized trials on this association were available. We also performed a cumulative meta-analysis and sensitivity analysis to assess the robustness of the results from the available studies.
METHODS

Search strategy and study selection
We searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, and ClinicalTrials.gov to identify randomized trials or observational studies that had been published up to July 13, 2016 , and evaluated the association between exposure to PDE5 inhibitors and risk for development of skin cancer. We searched for a combination of the terms sildenafil or vardenadil or avanafil or tadalafil or phosphodiesterase type 5 or phosphodieterase-5 or PDE5 and melanoma or basal cell carcinoma or squamous cell carcinoma or skin cancer without any restriction. We selected the studies according to the following inclusion criteria: (1) randomized controlled trials, cohort studies, or casecontrol studies; (2) studies comparing PDE5 inhibitors with placebo or non-PDE5 inhibitors; (3) follow-up for at least 52 weeks (not applicable to case-control studies), because little information relevant to cancer incidence was reported in studies of shorter duration; and (4) reporting of the outcomes of skin cancer. The primary outcome of interest was risk for development of melanoma, and secondary outcomes included basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). We excluded conference abstracts because they offer limited information with which to assess study quality, population, and outcomes.
Data extraction and quality assessment
We collected information on study design, drug use, study location, characteristics of participants, selection criteria, definition of exposure, adjusted covariates, and outcomes of interest. Data on outcomes such as adjusted hazard ratio, adjusted risk ratio, and adjusted odds ratio (OR) were extracted if appropriate. The Cochrane risk of bias tool for randomized trials 11 and the Newcastle-Ottawa scale (NOS) for observational studies 12 were used to assess quality. For NOS criteria, a maximum of 9 stars would be allocated to the following domains: selection, comparability, and outcome/exposure, with higher scores indicating better quality. Two reviewers (H.T. and W.W.) independently extracted the data and assessed the quality of each study. Any disagreements were resolved by consensus or referral to a third reviewer (J.H.). This meta-analysis of 5 observational studies suggested a slight but significant association between PDE5 inhibitors and both melanoma and basal cell carcinoma, with some evidence of heterogeneity. There were several limitations of this study, and future well-conducted prospective studies are warranted to assess the modest association.
CAPSULE SUMMARY
Statistical analysis
Adjusted ORs with the 95% confidence interval (CI) were used to pool the outcome data for users of PDE5 inhibitors compared with for nonusers. Although the effect measures differed between cohort studies (hazard ratio) and case-control studies (OR), they are relative measures, and these 2 effect estimates are close when the event rate is low (\5%). 13, 14 A random-effect meta-analysis model was used because of potential heterogeneity across studies. Statistical heterogeneity was further quantified by using the I 2 statistic, with I 2 values of less than 25%, 25% or higher to less than 75%, and 75% or higher indicating low, moderate, and high heterogeneity, respectively. 15 Furthermore, metaregression and subgroup analyses were performed to determine whether the pooled estimates were affected by total dose (low dose vs medium dose vs high dose), region of study (Europe vs the United States), type of design (cohort study vs case-control study), and specific PDE5 inhibitors (sildenafil vs vardenafil vs tadalafil). The definitions of low dose, medium dose, and high dose in each study are presented in Supplemental Table I (available at http://www.jaad.org). A sensitivity analysis omitting each study successively and a cumulative metaanalysis by order of publication year were carried out to assess the robustness of our findings. In addition, publication bias for risk for development of melanoma was assessed by using the Begg test and the Egger test, as well as by visual inspection of the funnel plots. All statistical analyses were performed with STATA, version 14 (StataCorp, College Station, TX). 
RESULTS
Study selection and study characteristics
Of 294 citations retrieved from electronic databases, 3 cohort studies 5, 7, 8 and 2 case-control studies 6,9 involving a total of 998,456 participants met the eligibility criteria and were included in our meta-analysis (Fig 1) . No randomized studies were identified. The characteristics of the included studies are presented in Table I . In total, 15,916 incident melanoma cases came from 5 studies, 46,785 incident BCC cases came from 4 studies, and 637 incident SCC cases came from 2 studies. However, 2 studies were performed by using the UK Clinical Practice Research Datalink, 7, 8 which might have some overlapping patients. Both studies were included because they differed in study design and selection criteria. One study used a cohort study design including male patients from 1998 to 2014 who had erectile dysfunction that was newly diagnosed when they were 40 years or older and men without any type of skin cancer diagnosis who were never prescribed PDE5 inhibitors before cohort entry. 7 The other study used a matched cohort study design including male patients from 1999 to 2014 who were age 18 or older and without any prior cancer diagnosis and those who were prescribed a PDE5 inhibitor as the exposures matched to 4 unexposed controls. 8 The included studies were of adequate quality, with more than 7 stars out of 9 in the NOS quality assessment (Supplemental Table II ; available at http://www.jaad.org).
Meta-analysis
The meta-analysis demonstrated that PDE5 inhibitors increased the risk for development of melanoma (adjusted OR, 1.12; 95% CI, 1.03-1.21; I 2 = 49.1%) and BCC (adjusted OR, 1.14; 95% CI, 1.09-1.19; I 2 = 49.5%), with moderate heterogeneity. In contrast, there was no evidence of any increased risk for development of SCC among users of PDE5 inhibitors (adjusted OR, 1.04; 95% CI, 0.78-1.37; I 2 = 16.9%) (Fig 2) .
Furthermore, meta-regression and subgroup analyses were performed to examine the source of heterogeneity (Table II) . The subgroup analysis by dose showed that the adjusted risk for development of melanoma was 1.06 (95% CI, 0.95-1.19; I 2 = 60.2%) for low-dose users, 1.11 (95% CI, 1.05-1.18; I 2 = 0%) for medium-dose users, and 1.08 (95% CI, 1.00-1.18; I 2 = 13.3%) for high-dose users ( Supplemental Fig 1; available at http://www.jaad.org). Additionally, our meta-regression analysis indicated that the risk was not statistically different across the 3 dose subgroups (P for interaction = .62 
Sensitivity analysis and publication bias
The significant association between PDE5 inhibitor use and increased risk for development of melanoma remained robust in the sensitivity analysis when each study was successively omitted (Supplemental Fig 5; 8 (OR, 1.11; 95% CI, 1.00-1.24) was similar to the primary result. Our cumulative meta-analysis ordered by publication year indicated that PDE5 inhibitor use was associated with a slight increase in risk for development of melanoma, and the point estimate gradually moved toward the null as the CI narrowed (Supplemental Fig 6; available at http://www.jaad. org). There was no evidence of substantial publication bias based on the Egger test (P = .12), the Begg test (P = .09), or visual inspection of the funnel plot ( Supplemental Fig 7; available at http:// www.jaad.org).
DISCUSSION
Our meta-analysis of 5 observational studies involving a large number of total participants and incident cases of skin cancer provides evidence that PDE5 inhibitor use is slightly but significantly associated with increased risk for development of melanoma and BCC, but not SCC. With regard to risk for development of melanoma, there was no evidence of dose-dependent association with PDE5 inhibitor use. On the basis of the results of a meta-regression, no other prespecified factors (study design, study region, or type of PDE5 inhibitor) significantly affected the overall results. A significantly increased risk for development of melanoma was found in European populations, but not in US populations. Our cumulative meta-analysis indicated a weak association, and the point estimate gradually moved toward the null. Furthermore, the sensitivity analysis omitting each study successively confirmed the robustness of our results. However, our results should be interpreted with caution owing to heterogeneity across studies. Several laboratory studies have reported that PDE5 inhibitors might promote melanoma cell growth and migration through activation of the cGMP pathway. [2] [3] [4] Recently, a cGMP-dependent mitogen-activated protein kinase pathway was identified in melanoma cells as the link between sildenafil use and increased risk for development of melanoma. 4 Nevertheless, laboratory studies are warranted to examine the effect of the intermittent use of PDE5 inhibitors on inducing irreversible changes in gene expression and promoting melanoma development. 5 However, evidence of an epidemiologic association between the use of PDE5 inhibitors and risk for development of melanoma remains inconsistent. One study showed that PDE5 inhibitor use was not associated with overall elevated risk for development of melanoma, although the risk was significantly higher among those who had received 7 or more prescriptions or 25 or more pills. 7 Our findings did not indicate a strong dose-response relationship between the use of PDE5 inhibitors and risk for development of melanoma. Therefore, we must interpret this association with caution.
We found a significantly increased risk for development of melanoma associated with PDE5 inhibitors only in European populations and not in US populations. It should be noted that an increased risk for development of melanoma was observed in US populations, but it did not reach statistical significance. Factors that might explain the differences in risk for development of melanoma associated with PDE5 inhibitor use among these populations include socioeconomic and cultural differences. Furthermore, the association between PDE5 inhibitor use and risk for development of melanoma might be influenced by potential confounders. Matthews et al showed that this significant association might be confounded by greater sun exposure among users of PDE5 inhibitors. 8 Their post hoc analysis showed that solar keratosis was significantly associated with PDE5 inhibitor use, which indicated that men with higher sun exposure were more likely to take PDE5 inhibitors. However, further meta-analysis was limited by lack of data on sun exposure in individual studies. Additionally, our meta-analysis found a similar increase in risk for development of BCC, but there was no increase in the risk for development of SCC. Melanoma is more closely related to intermittent sun exposure, whereas nonmelanoma skin cancer is more related to chronic sun exposure. Further studies are necessary to clarify the potential effect modification and confounding by sun exposure. In addition, a study by Loeb et al indicated that PDE5 inhibitor users had higher educational levels and annual incomes, which were also significantly associated with risk for development of melanoma. Finally, the study by Potteg ard et al found an increased incidence for lower stage/grade of melanoma among PDE5 inhibitor users than among nonusers, which suggested that the slightly elevated risk for development of melanoma might be attributable to more health-seeking behaviors, resulting in earlier detection. 9 The causality remains elusive, and further well-conducted large-scale prospective studies or randomized trials are still needed to confirm our findings.
Our study has several strengths. First, to our knowledge, this is the only meta-analysis to address the association between PDE5 inhibitors and risk for development of melanoma by including all relevant literature to date. Second, we performed subgroup analysis, sensitivity analysis, and cumulative metaanalysis to confirm the robustness of our findings. We also acknowledge that our meta-analysis has several limitations. First, no randomized controlled trials were identified, despite a systematic search of electronic databases. Second, doses were stratified differently across studies; this might have contributed to the observed heterogeneity, which might also have affected the results of our subgroup analysis by dose. Third, 2 studies were performed in the same database over the same time period, which might result in some overlapping patients. 7, 8 Both studies were included because they differed in study design and patient selection. Furthermore, excluding each study produced results similar to the primary results. Fourth, we were unable to determine the potential confounding effect of ultraviolet radiation exposure, skin type, or family history of melanoma. In addition, adjustment among studies for other confounders (eg, age, immunosuppression, social economic status, and marital status) was inconsistent. Finally, our meta-analysis detected statistical heterogeneity, which might be due (at least in part) to the study of different geographic regions.
In conclusion, some evidence suggests that use of PDE5 inhibitors may be slightly associated with increased risk for development of melanoma and BCC, but not SCC. Further large, well-conducted prospective studies with clear definitions of dose and 
